Introduction
============

*Clostridium difficile* is the primary cause of pseudomembranous colitis and a major cause of antibiotic-associated diarrhea.[@b1-ccrep-2-2009-005] In the original report of *C. difficile* published in 1935 the bacterium was named "the difficult clostridium" because early attempts at isolation were unsuccessful and it grew slowly in culture.[@b3-ccrep-2-2009-005]

*C. difficile* produces an enterotoxin (toxin A) and a cytotoxin (toxin B). Toxin A has been shown to be the cause of diarrhea and pseudomembranous colitis.[@b4-ccrep-2-2009-005]

*C. difficile* has rarely been reported to cause extraintestinal disease.[@b1-ccrep-2-2009-005] The role of toxins A and B in extracolonic manifestations of *C. difficile* remains unclear. We report a case of *C. difficile* bacteremia in a Crohn's disease patient and review the literature on previously reported cases.

Methods
=======

A review of the published literature on *C. difficile* bacteremia was done using MEDLINE and PubMed databases. Searches were conducted to find articles from 1966--2008. Medical subject headings used to search the databases included *C. difficile*, including subheadings of bacteremia, extraintestinal disease and Crohn's disease, as well as a keyword search using "*C. difficile* bacteremia." Titles and abstracts of potentially relevant articles were reviewed by a single author.

Case Report
===========

We describe the case of a 50-year-old white male with small bowel Crohn's disease initially admitted with nausea and abdominal distention secondary to a small bowel obstruction. The patient has a 30 year history of Crohn's disease involving the jejunum and terminal ileum with multiple proximal small bowel strictures. He has had an appendectomy and back surgery in the past but was never treated surgically for his Crohn's disease. He was on maintenance therapy with Azulfidine and Azathioprine. The patient was started on Infliximab in November 2005 after multiple admissions for small bowel obstruction. The patient was changed to Adalimumab in May 2007 for patient convenience and difficulty related to obtaining regular intravenous access. He denied any recent antibiotic use.

Computerized tomography scanning on admission demonstrated a small bowel obstruction with thickened and edematous small bowel in the right lower quadrant 8--10 cm from the ileocecal valve with a small amount of ascites and no evidence of abscess. A nasogastric tube was placed for decompression and the patient was placed on solumedrol 20 mg intravenous (iv) every eight hours along with aggressive iv hydration and pain management with hydromorphone. The patient initially improved on hospital day number one. On the morning of hospital day number 2, the patient was reported to be febrile to 39.4 ºC and tachycardic. The patient was complaining of increased pain and on exam had significantly increased tenderness with absent bowel sounds. At that time, the blood culture drawn on admission was reported as growing *Escherichia coli, Enterococcus fecalis and Klebsiella oxytoca.* The patient was started on intravenous antibiotics (ampicillin/sulbactam and gentamicin) and taken for an emergent laparotomy. He was found to have a perforation with a free abdominal abscess and a partial small bowel obstruction of the jejunum. The patient underwent a small bowel resection with jejunojejunal anastamosis and a right hemicolectomy with ileocolonic anastamosis and ileostomy. The pathology revealed a T4N1 poorly differentiated adenocarcinoma of the jejunum. The patient did well clinically post-op however a routine blood culture drawn for fever on post-op day number one grew *Clostridium difficile*. The patient denied significant diarrhea. Subsequent stool studies sent for *Clostridium difficile* toxins A/B were negative. At that time, the patient had received four days of antibiotics. The patient was maintained on pipercillin-tazobactam. All other follow-op blood cultures were unremarkable. The patient received a total of 21 days of intravenous antibiotics (6 days of ampicillin/sulbactam and gentamicin followed by 15 days of pipercillin-tazobactam). The remainder of his post-op course was unremarkable and he made a full recovery.

Discussion
==========

We report the first case of *C. difficile* bacteremia in a Crohn's disease patient. There are 15 other reported cases of *C. difficile* bacteremia reported in the literature that are summarized in [Table 1](#t1-ccrep-2-2009-005){ref-type="table"}. The prevailing theory regarding the pathophysiology of *C. difficile* bacteremia is that the colonic wall inflammation associated with pseudomembranous colitis permits transient bacteremia to develop.

The overall mortality rate is significant, with 6 of 15 reported patients dying. In terms of the demographics, 11 of the 15 patients were male and the age range was from neonate to age 69. A high proportion (4 of the 15 patients) had an underlying malignancy. Unfortunately, *C. difficile* stool toxin was sent in only 7 of the patients. The stool toxin was positive in 5 out of the 7 patients. *C. difficile* Associated Diarrhea (CDAD) was reported in 6 out of the 7 patients. Two out of the 5 patients with positive stool toxin died. The majority of patients (10 of 15 patients) had polymicrobial bacteremia. Four of the reported cases occurred postoperatively.

Recent antibiotic use was found to be a significant risk factor. Antibiotic use leads to an alteration of the intestinal microflora, leading to overgrowth of endogenous *C. difficile* or allowing colonization by nosocomial *C. difficile*. Only 12 of the case reports comment on antibiotic exposure (9 of 12 patients had antibiotic exposure). Cephalosporins were the most common class of antibiotics that these patients were exposed to.

Information on therapy is available on 11 of the patients. The activity of various drugs against *C. difficile* according to the Manual of Clinical Microbiology is summarized in [Table 2](#t2-ccrep-2-2009-005){ref-type="table"}. Among the cases reviewed, 4 were treated with metronidazole (2 of which died). The specification of oral versus intravenous therapy was incomplete. It is important to note that the two patients who died were both neutropenic leukemic patients. There were 7 patients that were treated (at least in part) with vancomycin and they all survived except one. Two of these patients were treated exclusively with oral vancomycin and they both survived. One of the patients was treated only with intravenous vancomycin and survived. There was also one patient treated with both oral and intravenous vancomycin who survived. The remaining three patients were treated with a regimen that included other antibiotics. In our case, the patient was successfully treated with pipercillin-tazobactam.

*C. difficile* is a ubiquitous organism that can be found in the environment and exposure to the organism is common. It has been estimated that 15%--25% of adults become colonized after admission to the hospital.[@b16-ccrep-2-2009-005] There is also growing literature to support a strong link between inflammatory bowel disease and *C. difficile* infection. Previous studies have demonstrated that 5%--20% of patients admitted with an IBD flare will have *C. difficile* infection.[@b16-ccrep-2-2009-005] The growing literature support for the link between IBD flares and *C. difficile* infection along with the significant mortality associated with *C. difficile* bacteremia highlight the importance of this topic.

In conclusion, we find that *C. difficile* bacteremia is associated with a significant mortality rate. *C. difficile* Associated Diarrhea (CDAD) was reported in 6 out of the 15 patients. Not surprisingly, the majority of patients had recent antibiotic exposure. We found a high proportion of patients were male. We also found that the majority of patients had a polymicrobial bacteremia. Therefore, it is unclear if *C. difficile* is the primary pathogen. In terms of treatment, it would seem prudent to consider aggressive antibiotic therapy given the high mortality rate.
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###### 

Previous Reported Cases of *Clostridium difficile* Bacteremia.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                   Sex/Age     Clinical presentation                                                                                Stool *C. difficile*   Other organisms isoloated                                    Antibiotic exposure                     Treatment                           Outcome
  --------------------------- ----------- ---------------------------------------------------------------------------------------------------- ---------------------- ------------------------------------------------------------ --------------------------------------- ----------------------------------- ----------
  \#[@b5-ccrep-2-2009-005]    M/5         URI                                                                                                  NR                     None                                                         NR                                      NR                                  NR

  \#[@b6-ccrep-2-2009-005]    M/68        Cirrhotic admitted with bacteremia, ascites, and spleenic abscess                                    NR                     None                                                         None                                    Penicillin G                        Died

  \#[@b7-ccrep-2-2009-005]    M/neonate   Necrotic small bowel with peritonitis and bacteremia                                                 NR                     Staphylococcus epidermedis (likely procedural contaminant)   Ampicillin and kanamycin                Surgery, ampicillin and kanamycin   Died

  \#[@b8-ccrep-2-2009-005]    M/65        Toe gangrene with septicemia                                                                         Negative               Bacteroides fragilis                                         Cefuroxime                              Oral vancomycin                     Survived

  \#[@b9-ccrep-2-2009-005]    F/35        AML patient admitted with neurtopenic fever/sepsis                                                   Positive               Bacteroides sp, group D steptococci                          Cefotaxime + Gentamicin                 Metronidazole (iv)\                 Died
                                                                                                                                                                                                                                                                           Oral vancomycin                     

  \#[@b9-ccrep-2-2009-005]    F/69        ALL patient admitted with neutropenic fever/sepsis                                                   Positive               Bacteroides sp, Escherichia coli                             Metronidazole\                          Metronidazole                       Died
                                                                                                                                                                                                                                   Ampicillin\                                                                 
                                                                                                                                                                                                                                   Cloxacillin\                                                                
                                                                                                                                                                                                                                   Cotrimazole\                                                                
                                                                                                                                                                                                                                   Gentamicin                                                                  

  \#[@b10-ccrep-2-2009-005]   M/62        Splenic abscess with bacteremia                                                                      NR                     Pseudomonnas paucimobilis (spleen only)                      Pipercillin\                            Metronidazole\                      Survived
                                                                                                                                                                                                                                   Netilmycin                              Cefoxitin                           

  \#[@b11-ccrep-2-2009-005]   M/39        Oropharyngeal cancer patient admitted with mandible radionecrosis                                    Positive               Escherichia coli\                                            None                                    Metronidazole (iv)\                 Survived
                                                                                                                                                                      Enterococcus fecalis\                                                                                Vancomycin(iv)\                     
                                                                                                                                                                      Bacteroides vulgatos                                                                                 Pefloxacin                          

  \#[@b1-ccrep-2-2009-005]    F/85        Nosocomial *C. diff.* colitis complicated by bacteremia                                              Positive               Enterococcus fecalis                                         Ticacillin/Clavulanic acid              Vancomycin(iv)\                     Survived
                                                                                                                                                                                                                                                                           Gentamcin                           

  \#[@b12-ccrep-2-2009-005]   M/17        Duchenne musculai dystrophy patient admitted with partial small bowel obstructionr                   NR                     Candida Parapsilosis                                         NR                                      NR                                  Survived

  \#[@b12-ccrep-2-2009-005]   F/33        Cervical cancer patient admitted with pelvic abscess and rectovaginal fistula after radiation        NR                     *Clostridium* cadaveris\                                     NR                                      NR                                  Died
                                                                                                                                                                      Bacteroides melaninogenicus                                                                                                              

  \#[@b12-ccrep-2-2009-005]   M/77        Perforated sigmoid diverticulum                                                                      NR                     Eubacterium lentum                                           NR                                      NR                                  Died

  \#[@b13-ccrep-2-2009-005]   M/3         Tonsilitis followed by pericarditis and diarrhea                                                     NR                     None                                                         Amoxicillin/Clavulonic acid, Cefixime   Vancomycin (iv)\                    
                                                                                                                                                                                                                                                                           Survived                            

  \#[@b14-ccrep-2-2009-005]   M/18        Abdominal pain and diarrhea after course of antibiotics for exudative sore throat                    Positive               None                                                         Erythromycin                            Oral Vancomycin                     Survived

  \#[@b14-ccrep-2-2009-005]   M/78        Admitted after trauma, treatment for aspiration pneumonia complicated by *C. difficile* bacteremia   Negative               None                                                         Cefuroxime\                             Vancomycin (oral and iv)            Survived
                                                                                                                                                                                                                                   Amikacin                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** URI, upper respiratory infection; NR, not reported; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; IV, intravenous.

###### 

Activity of various drugs against *C. difficile*.

  Antimicrobial agent             CLSI MIC breakpoint (μg/ml)   *C. difficile* % susceptibility   
  ------------------------------- ----------------------------- --------------------------------- ------
  Ampicillin                      0.5                           1                                 26%
  Amoxicillin-clavulanate         4/2                           8/4                               100%
  Pipercillin-tazobactam          32/4                          64/4                              100%
  Ticarcillin                     32                            64                                100%
  Clindamycin                     2                             4                                 56%
  Vancomycin                      8                             16                                100%
  Imipenem                        4                             8                                 94%
  Linezolid                       2                             4                                 91%
  Metronidazole                   8                             16                                100%
  Trimethoprim-sulfamethoxazole   32                            64                                26%
  Trovfloxacin                    2                             4                                 86%

Clinical and Laboratory Standards Institute (CLSI) approved method M11-A6(50a); data from Wadsworth Anaerobic Bacteriology. Johnson EA, Summanon P, Finegold SM. *Manual of Clinical Microbiology*, 9th ed. 2007; 904--905.
